Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trněný M, Verhoef G, Dyer MJ, Yehuda DB, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 May 10. pii: haematol.2017.168401. doi: 10.3324/haematol.2017.168401. [Epub ahead of print]

2.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064. Review.

3.

The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.

PMID:
29318369
4.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

PMID:
29083050
5.

[Novel Findings in Follicular Lymphoma Pathogenesis and the Concepts of Targeted Therapy].

Deván J, Musilová K, Janíková A, Mráz M.

Klin Onkol. 2017 Summer;30(4):247-257. doi: 10.14735/amko2017247. Czech.

PMID:
28832170
6.

[The Importance of MicroRNA Deregulation in the Molecular Pathogenesis and Histological Transformation of Follicular Lymphoma].

Musilová K, Deván J, Zlámalíková L, Křen L, Móciková H, Procházka V, Mayer J, Trněný M, Janíková A, Mráz M.

Klin Onkol. 2017 Spring;30(Supplementum1):163-165. Czech.

PMID:
28471196
7.

Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.

Procházka V, Papajík T, Janíková A, Belada D, Kozák T, Šálek D, Sýkorová A, Móciková H, Campr V, Dlouhá J, Langová K, Fürst T, Trněný M.

Leuk Lymphoma. 2017 Mar;58(3):601-613. doi: 10.1080/10428194.2016.1213834. Epub 2016 Sep 25.

PMID:
27666539
8.

[Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].

Sýkorová A, Pytlík R, Móciková H, Belada D, Benešová K, Papajík T, Janíková A, Šálek D, Procházka V, Vokurka S, Campr V, Klener P, Kubáčková K, Trněný M.

Klin Onkol. 2016;29(4):295-302. Czech.

PMID:
27534788
9.

Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.

Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M; Czech Lymphoma Study Group.

Leuk Lymphoma. 2016 Dec;57(12):2777-2783. Epub 2016 Apr 18.

PMID:
27087066
10.

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF.

Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25.

PMID:
26687959
11.

Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova J, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Leuk Lymphoma. 2016 May;57(5):1094-103. doi: 10.3109/10428194.2015.1079313. Epub 2015 Oct 12.

PMID:
26293000
12.

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16μg/kg/day: efficacy and safety.

Krejci M, Janikova A, Folber F, Kral Z, Mayer J.

Neoplasma. 2015;62(5):787-92. doi: 10.4149/neo_2015_094.

PMID:
26278142
13.

Radiotherapy in early stage follicular lymphoma: is it really the gold standard?

Janikova A.

Leuk Lymphoma. 2015;56(10):2999-3000. doi: 10.3109/10428194.2015.1049172. Epub 2015 Jun 18. No abstract available.

PMID:
25985811
14.

[Vitamin D during cancer treatment].

Tomíška M, Novotná Š, Klvačová L, Tůmová J, Janíková A.

Klin Onkol. 2015;28(2):99-104. Review. Czech.

PMID:
25882019
15.

Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.

Chovancová J, Bernard T, Stehlíková O, Šálek D, Janíková A, Mayer J, Doubek M.

Cytometry B Clin Cytom. 2015 Mar;88(2):92-100. doi: 10.1002/cyto.b.21210. Epub 2015 Jan 14.

16.

Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel 8-Color Flow Cytometry Approach.

Chovancová J, Bernard T, Stehlíková O, Sálek D, Janíková A, Mayer J, Doubek M.

Cytometry B Clin Cytom. 2014 Nov 28. doi: 10.1002/cytob.21210. [Epub ahead of print]

17.

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, Duras J, Mocikova H, Mayer J, Trneny M.

Leuk Lymphoma. 2015;56(8):2350-6. doi: 10.3109/10428194.2014.990010. Epub 2015 Jan 21.

PMID:
25426666
18.

A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.

Procházka V, Pytlík R, Janíková A, Belada D, Sálek D, Papajík T, Campr V, Fürst T, Furstova J, Trněný M.

PLoS One. 2014 Jul 24;9(7):e102594. doi: 10.1371/journal.pone.0102594. eCollection 2014.

19.

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G.

J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12.

PMID:
24821885
20.

Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma.

Janikova A, Mareckova A, Baumeisterova A, Krejci M, Supikova J, Salek D, Horky O, Tichy B, Hanke I, Pospisilova S, Moulis M, Mayer J.

Leuk Lymphoma. 2014 Aug;55(8):1935-8. doi: 10.3109/10428194.2013.858150. Epub 2014 Feb 14. No abstract available.

PMID:
24160848

Supplemental Content

Loading ...
Support Center